Relating to the manufacture, sale, and distribution of products developed using mRNA material in the prevention or treatment of a communicable disease.

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 1 History 3 Sponsors

Mar 20, 2025 · House

Read first time

Mar 20, 2025 · House

Referred to Public Health

Feb 21, 2025 · House

Filed

PASSAGE PROBABILITY

1% Unlikely

Why this number

Stage base In Committee — base rate 11%, measured from TX's completed sessions
Momentum -1 45/100 from the pace of recorded action
Time since last action -22 574 days quiet

A transparent scoring model over stage, momentum, recency, sponsorship and recorded votes — not a trained predictor. Treat it as a way to rank attention, not as a forecast.